Study to Evaluate the Safety and Immune Response of an Investigational Vaccine for the Prevention of RSV (Respiratory Syncytial Virus) and (hMPV) Human Metapneumovirus Infection in Participants Aged 60 to 75 Years

Trial Identifier: VAV00039
Sponsor: Sanofi Pasteur, a Sanofi Company
Start Date: October 2024
Primary Completion Date: August 2025
Study Completion Date: August 2025
Condition: Metapneumovirus immunisation; Respiratory Syncytial Virus Immunisation

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

No locations posted.